These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 20857129)

  • 1. Definition of treatment goals for moderate to severe psoriasis: a European consensus.
    Mrowietz U; Kragballe K; Reich K; Spuls P; Griffiths CE; Nast A; Franke J; Antoniou C; Arenberger P; Balieva F; Bylaite M; Correia O; Daudén E; Gisondi P; Iversen L; Kemény L; Lahfa M; Nijsten T; Rantanen T; Reich A; Rosenbach T; Segaert S; Smith C; Talme T; Volc-Platzer B; Yawalkar N
    Arch Dermatol Res; 2011 Jan; 303(1):1-10. PubMed ID: 20857129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?
    Jacobi A; Weidemann-Röver B; Barbus S; Mrowietz U
    Dermatology; 2022; 238(2):292-300. PubMed ID: 34107489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment goals for moderate to severe psoriasis: an Australian consensus.
    Baker C; Mack A; Cooper A; Fischer G; Shumack S; Sidhu S; Soyer HP; Wu J; Chan J; Nash P; Rawlin M; Radulski B; Foley P
    Australas J Dermatol; 2013 May; 54(2):148-54. PubMed ID: 23330815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 9. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.
    Al-Oudah GA; Sahib AS; Al-Hattab MK; Al-Ameedee AA
    J Popul Ther Clin Pharmacol; 2022; 29(2):e52-e60. PubMed ID: 35848197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.
    Prevezas C; Katoulis AC; Papadavid E; Panagakis P; Rigopoulos D
    Skin Appendage Disord; 2019 Nov; 5(6):344-349. PubMed ID: 31799260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
    van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.